drug
talimogene laherparepvec
Marketedupdated 3mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying talimogene laherparepvec
- phase2Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
- phase1Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
- phase2TVEC and Preop Radiation for Sarcoma (8 ml Dose)
- phase2Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
- phase2A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- EP1Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
- phase1T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
- phase2A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
News(1)
- Replimune’s twice-rejected melanoma drug prevails in FDA adcommFollowing a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.fiercebiotech · 12d ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that